What the Maudsley Deprescribing Guidelines Add to the Ashton Manual

What do the Maudsley Deprescribing Guidelines add to the Ashton Manual?

The Ashton Manual taught doctors and patients how to come off of a benzodiazepine slowly, and the Maudsley Deprescribing Guidelines explain why the slow part has to get slower as the dose gets smaller. That is the short answer. The Manual came out of one withdrawal clinic in England, and the Maudsley guidelines arrived in 2024 with the pharmacology that the Manual’s schedules had been following by feel.

Dr. Leeds tapers by both references, never by the Ashton Manual alone. Neither one is a schedule to copy, and both say so in their own words. So, what did each of them actually establish, and where does one pick up where the other leaves off?

The Ashton Manual established that a prescribed dose can cause dependence.

Professor C. Heather Ashton wrote the Manual after running a benzodiazepine withdrawal clinic at Newcastle University for twelve years. Its first chapter explains how benzodiazepines work at the gamma-aminobutyric acid (GABA) receptor, and how the brain adapts to them until the drug is needed just to feel normal. She called this therapeutic dose dependence, and she made the point that it happens to people who took their medication exactly as prescribed.

That point still matters, because a family member or a hurried doctor will often hear “dependent” and think “addicted.” Dependence is not addiction. A person with physical dependence has a nervous system that has adjusted to a drug, and the treatment for that is a medical taper, not an addiction treatment.

The Manual is free to read at benzo.org.uk, and Dr. Leeds still points patients to it as the place to start. Chapter I is where a patient learns why they feel worse between doses, and Chapter II is where they learn why “just stop taking it” is dangerous advice. The method in the Ashton Manual has not been replaced. It has been explained.

The Manual made slow withdrawal, at the patient’s pace, the rule.

Chapter II of the Ashton Manual is the part most people know. It lays out numbered withdrawal schedules, and it says plainly that they are only guides, with the rate of reduction decided by the patient rather than the doctor. Professor Ashton expected a taper to take months, and often a year or more, and she saw no virtue in hurrying.

The Manual’s other well-known move is the crossover taper to diazepam, or Valium. Diazepam leaves the body slowly, so the level in the blood stays even between doses, and it comes in small tablet strengths and a liquid, so the steps down can be small. Her equivalence table, Table 1, is what a doctor uses to work out what a dose of Xanax or Klonopin comes to in diazepam.

Fortunately, the Manual also names what comes after. Chapter III describes acute and protracted withdrawal symptoms, and it tells the reader that a long tail of symptoms after the last dose is real and does fade. Time heals, slowly.

What did the Ashton Manual leave unexplained?

Look closely at the schedules and you will notice that the steps shrink toward the end. A schedule that starts by cutting a few milligrams at a time ends by cutting a fraction of a milligram at a time. Professor Ashton learned that from her patients, and the Manual presents it as practical experience rather than as a law of pharmacology.

Unfortunately, experience without an explanation is easy to argue with. A doctor who has never run a withdrawal clinic looks at a patient on a low dose of diazepam and cannot see why the last few milligrams should take as long as everything that came before. The patient feels it. The doctor does not, and the taper gets pushed.

The Manual also lists zolpidem, or Ambien, and the other z-drugs in Table 1 as drugs that have the same effects and act by the same mechanisms as benzodiazepines, but it does not walk through how to taper them. It described the shape of a good taper. It did not yet have the picture of the receptor to explain the shape.

The Maudsley guidelines explain why the cuts must get smaller.

The Maudsley Deprescribing Guidelines, published in 2024, cover benzodiazepines and z-drugs in detail. Their central idea is receptor occupancy. The share of GABA receptors a benzodiazepine is acting on does not rise in a straight line with the dose. It rises steeply at low doses and then flattens, so that at higher doses most of the receptors are already occupied and adding more drug changes little.

Run that curve backward and the problem with equal cuts appears. Taking a fixed amount off a high dose barely moves receptor occupancy, because the receptors were nearly full anyway. Taking the same fixed amount off a low dose removes a large share of the drug’s effect all at once, and that is the drop the nervous system feels as withdrawal.

So, the guidelines recommend reductions that are a proportion of the current dose, which means each cut is smaller than the one before, with the final dose before stopping very small indeed. The guidelines call this hyperbolic tapering, after the shape of the curve. No one has proven a single best rate, and in practice the rate is set by what the patient tolerates. It is the Manual’s shrinking steps, stated as a principle rather than a habit.

Think of the receptors as a parking lot.

An analogy that might help is a parking lot with a fixed number of spaces and a line of cars waiting to get in. When the line is long, sending twenty cars home changes nothing that you can see from the lot. Every space is still full, and the line is just a little shorter.

Now imagine the same lot on a quiet evening, with a handful of cars parked and no line at all. Send twenty cars home, and the lot is empty. The number of cars you removed was the same both times, and the effect on the lot was not even close.

While this is not a perfect analogy, the receptors are the spaces and the drug molecules are the cars. At a high dose, the lot is full and a cut goes unnoticed. At a low dose, every car counts, and the cuts have to shrink to match. That is the whole of hyperbolic tapering in one picture.

Maudsley carries the same reasoning across benzodiazepines and z-drugs.

The Manual’s schedules run through diazepam. The Maudsley guidelines take up benzodiazepines and z-drugs drug by drug, and the same receptor reasoning applies whether the drug is alprazolam, or Xanax, clonazepam, or Klonopin, lorazepam, or Ativan, or a sleeping pill such as zolpidem, or Ambien. A person dependent on a sleeping pill gets the same explanation as a person dependent on a daytime benzodiazepine, because both drugs act at the same GABA receptor.

The switch to diazepam is an option rather than a rule. A patient may instead taper the drug they are already on, using a liquid or a compounded preparation to make the small cuts, and not every patient tolerates the change. The hold matters as much as the cut. When symptoms flare after a reduction, the sensible course is to stay at the current dose until things settle, not to push on.

In fact, one of the most useful passages has nothing to do with dose arithmetic. The guidelines take care to separate withdrawal symptoms from the return of the original anxiety or insomnia, because that mistake sends a patient back onto a full dose or onto a new drug. Anyone who has been told that their withdrawal is “just your anxiety coming back” will recognize the page. The same volume covers other psychiatric medications, which Dr. Leeds also helps patients taper, though that is a subject for another day.

Dr. Leeds tapers by both references, never by the Ashton Manual alone.

In his practice, the two references do different jobs. The Ashton Manual supplies the crossover taper and the rule that the patient sets the pace. The Maudsley guidelines supply the shape of the reductions and the reason a cut that felt like nothing at a high dose can feel like a cliff at a low one.

Dr. Leeds still prefers the diazepam crossover the Manual recommends for most patients, because in his experience patients who can make the switch tend to have a smoother taper. Yet, he applies the Maudsley shape to that diazepam, with compounded liquid formulations that allow cuts of a fraction of a milligram when the dose gets low. Where diazepam does not suit a patient, the same proportional reductions are applied to the benzodiazepine they are already taking.

A common pattern he sees is a patient who did well for months on equal-sized cuts, then hit a wall in the last stretch and decided that something was wrong with them. Nothing was wrong with them. The cuts had simply stopped shrinking, and the parking lot had emptied out. Holding, then changing the size of the reductions, is usually what gets the taper moving again.

Neither reference is a schedule to copy.

Neither book presents itself that way. The Manual’s schedules are described as guides, and the Maudsley approach is built on adjusting each step to what the patient can tolerate. A schedule printed on a page cannot feel a bad week, and a taper that ignores a bad week is how people get hurt.

The third reference Dr. Leeds keeps beside them is the 2020 boxed-warning update from the United States Food and Drug Administration (FDA). It states that physical dependence can occur even when a benzodiazepine is taken as prescribed, that stopping abruptly or reducing the dose too quickly can cause withdrawal reactions that can be life-threatening, and that a gradual taper should be used to reduce the dose or stop. Stopping a benzodiazepine suddenly can cause seizures. If someone has a seizure or a severe reaction after stopping, call 911.

What the three references share is the part that matters most. The patient sets the pace, the doctor watches for trouble and slows things down, and no one is asked to accept a plan they did not choose. That is what informed consent looks like in a taper: the risks explained first, the alternatives named, including staying at the current dose for now, and the right to say no to any step. Your taper is between you and your doctor.

Dr. Leeds is an osteopathic physician and deprescribing specialist in Fort Lauderdale, Florida, and he works with every patient himself, by telemedicine anywhere in Florida, on a taper built from the Ashton Manual, the Maudsley Deprescribing Guidelines, and what that patient’s nervous system says each week. If you are taking a benzodiazepine or a z-drug and want a taper that gets slower when it needs to, Contact the office to talk about how he works.

This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.